After more than fifty years of persistent scientific inquiry, an international consortium of researchers has finally pinpointed the genetic origin of a mysterious red blood cell marker, leading to the establishment of a new human blood group system, now officially designated MAL. This groundbreaking discovery offers crucial insights for transfusion medicine, particularly for the exceptionally rare individuals whose immune systems react to the AnWj antigen, previously an unexplained serological curiosity. The identification of the underlying gene promises to transform the way these patients are identified and how compatible blood is sourced, mitigating the risk of potentially life-threatening transfusion reactions.
The human circulatory system relies on a complex array of biological markers, particularly those found on the surface of red blood cells. While most individuals are familiar with the major ABO and Rh blood groups, these represent only a fraction of the intricate molecular landscape that defines an individual’s blood profile. Hundreds of distinct molecules adorn the membranes of red blood cells, many of which function as antigens—specific targets that the body’s immune system can recognize. In routine blood transfusions, ensuring compatibility across ABO and Rh systems is paramount. However, for patients possessing unusual antibodies or extremely rare blood types, matching these lesser-known antigens becomes absolutely critical to prevent adverse immunological responses.
The AnWj antigen first came to scientific attention in 1972, presenting a persistent puzzle. Despite its widespread presence in the human population, appearing in over 99.9% of individuals, the specific gene responsible for its production and the protein carrying it on red blood cells remained elusive for decades. For the minuscule fraction of people who are AnWj-negative, this distinction carries profound implications. Should an AnWj-negative individual develop antibodies against this antigen and subsequently receive AnWj-positive blood, these antibodies are primed to attack the transfused red blood cells, potentially initiating a severe hemolytic transfusion reaction. The challenge was further compounded by the dual nature of AnWj negativity: while some individuals inherently lack the antigen due to an inherited genetic predisposition, others may lose AnWj expression as a consequence of underlying hematological disorders or specific cancers. The extreme rarity of the inherited form, with only a handful of cases identified globally, significantly hampered earlier investigative efforts.
The definitive breakthrough emerged from collaborative efforts, notably involving scientists at NHS Blood and Transplant in Bristol, including experts from the International Blood Group Reference Laboratory (IBGRL), in partnership with colleagues at the University of Bristol. To finally uncover the source of the AnWj antigen, the research team employed whole exome sequencing, a sophisticated genetic technique that scrutinizes the protein-coding regions of DNA. This powerful methodology enabled researchers to scan thousands of genes for unusual genetic variants consistently shared among the affected individuals. Unexpectedly, this extensive analysis converged on the MAL gene.
The investigation revealed that individuals exhibiting the inherited AnWj-negative phenotype carried homozygous deletions affecting the MAL gene. Homozygous implies that identical genetic changes were present in both copies of the gene, one inherited from each biological parent. The MAL gene is responsible for synthesizing a small membrane protein named Mal. Upon examining red blood cells, the team observed that AnWj-positive individuals consistently produced the full-length Mal protein on their cell surfaces, whereas it was entirely absent from the cells of AnWj-negative individuals. The study meticulously included five genetically AnWj-negative individuals, among them members of an Arab Israeli family, whose participation was instrumental. Significantly, the samples also included blood donated in 2015 by the very first AnWj-negative woman identified back in the 1970s, providing a direct link to the historical mystery.
Identifying a genetic association was merely the initial step; the researchers recognized the imperative to unequivocally demonstrate that the Mal protein was indeed the direct carrier of the AnWj antigen. To achieve this, scientists conducted rigorous experimental validation. When the normal MAL gene was introduced into laboratory cells, these cells subsequently became reactive to AnWj antibodies, confirming the antigen’s presence. Conversely, introducing an altered form of the gene failed to elicit the same immunological response. Further meticulous experiments conclusively established that the Mal protein was both necessary and sufficient for the expression of the AnWj antigen on red blood cell surfaces. This crucial series of experiments provided the robust evidence required to elevate MAL to the status of a distinct blood group system, with AnWj serving as its defining antigen.
Louise Tilley, a Senior Research Scientist at IBGRL Red Cell Reference at NHS Blood and Transplant, reflected on the extensive effort: "The genetic background of AnWj remained an enigma for over five decades, a challenge I personally pursued for nearly twenty years of my career. This represents a monumental achievement and the culmination of a protracted team effort to finally establish this new blood group system. It empowers us to offer optimal care to a small but critically important patient population." Professor Ash Toye, Director of the NIHR Blood and Transplant Research Unit in red cell products at the University of Bristol, added, "It is truly exhilarating that we could leverage our expertise in manipulating gene expression within developing blood cells to conclusively confirm the identity of the AnWj blood group, a puzzle that has endured for half a century. This advancement will facilitate the identification of these rare donors and ultimately benefit patients in the future." The difficulty was amplified by the Mal protein itself; being a very small protein embedded in cell membranes, and previously associated with general membrane organization and cellular transport, it offered few immediate clues as a potential carrier for a mysterious red blood cell antigen.
Following this conclusive evidence, the International Society of Blood Transfusion (ISBT) formally ratified MAL as ISBT 047. This designation is far more significant than a mere addition to a nomenclature list. For an antigen to qualify as a recognized blood group system, researchers must rigorously demonstrate a direct connection between the antigen and a precisely defined genetic and molecular basis. At the time of its recognition, MAL became the 47th officially acknowledged blood group system. The field of immunohematology continues its rapid progression, as evidenced by the ISBT’s announcement in September 2026 of JAMA as the 49th blood group system, underscoring the ongoing expansion of our understanding of the human blood’s intricate genetic map. Nicole Thornton, Head of IBGRL Red Cell Reference at NHS Blood and Transplant, emphasized the dedication required: "Resolving the genetic basis for AnWj has been one of our most demanding projects. Proving that a gene actually encodes a blood group antigen involves extensive work, but it is precisely this kind of discovery for the benefit of rare patients globally that drives our passion."
The identification of the MAL gene fundamentally changes the landscape for blood specialists. It provides an unprecedented genetic tool to directly identify individuals who inherit AnWj-negative blood. Genotyping tests can now be meticulously designed to detect the relevant MAL genetic alterations in rare patients and potential donors, and these tests can be seamlessly integrated into existing blood group genotyping platforms. This capability is paramount, as finding compatible blood for someone who has developed antibodies against an antigen present in over 99.9% of the population is extraordinarily challenging. The urgency of this need is not merely theoretical; prior clinical reports have documented that anti-AnWj antibodies can indeed precipitate severe hemolytic transfusion reactions, where the recipient’s immune system systematically destroys transfused red blood cells.
Recent clinical cases further underscore the profound complexities involved. In 2026, clinicians reported on a 75-year-old man suffering from severe anemia who also presented with an anti-AnWj autoantibody. Given the unavailability of compatible blood, physicians, after carefully weighing the risks, made the difficult decision to transfuse unmatched red blood cells. Genetic testing subsequently confirmed his MAL gene was normal, reinforcing the conclusion that his antibody was acquired, rather than stemming from the rare inherited MAL deficiency. In this instance, he did not experience a hemolytic transfusion reaction. Another case from 2026 involved a patient diagnosed with high-grade B-cell lymphoma and a complement-binding anti-AnWj autoantibody. Following transfusions with incompatible blood that led to signs of red blood cell destruction, clinicians utilized sutimlimab, a medication designed to block a specific part of the immune complement pathway. While the patient’s laboratory markers showed improvement, researchers cautioned that the intricate nature of the case and the short treatment duration precluded drawing definitive conclusions about the treatment’s overall effectiveness. This instance was noteworthy as the first reported use of sutimlimab for this specific type of anti-AnWj-associated hemolysis. These compelling cases collectively highlight a critical distinction: some individuals are AnWj-negative due to inherited MAL gene variations, whereas others may lose AnWj expression as a manifestation of an underlying disease and subsequently develop an antibody against a marker their cells previously carried.
The narrative of the MAL blood group vividly illustrates the immense complexity often concealed behind the seemingly simple ABO system. Blood groups are fundamentally defined by inherited variations in the molecules adorning red blood cell surfaces. While these genetic differences typically have no discernible impact on daily life, their significance becomes acutely apparent when the immune system encounters red blood cells carrying an antigen it perceives as foreign, particularly during vital medical procedures like blood transfusions or during pregnancy. This inherent complexity is precisely why research into rare blood groups, despite involving a very small patient population, can yield disproportionately large clinical benefits. When a patient develops an antibody against an antigen present in almost every other human being, the quest for compatible donor blood can necessitate the expertise of highly specialized laboratories, access to rare donor registries, and often, extensive international collaboration.
Dr. Tim Satchwell, a Senior Lecturer at UWE Bristol who contributed to the study while a Research Fellow at the University of Bristol, noted the multifaceted approach required: "Mal is a very small protein with some interesting properties that made its identification challenging, necessitating multiple lines of investigation to gather the proof needed to establish this blood group system. The ability to combine our diverse expertise to finally achieve this has brought immense satisfaction to the entire team." For over five decades, AnWj existed as a blood antigen devoid of a known genetic home. The definitive identification of the MAL gene has fundamentally altered this landscape, providing researchers with a precise molecular explanation, equipping clinicians with a pathway towards more accurate genetic testing, and offering rare patients a significantly improved chance of being correctly identified before a challenging transfusion scenario escalates into a medical emergency. The official ISBT blood group database now lists the reference MAL allele alongside the null allele associated with the AnWj-negative phenotype, transforming what was once an enigmatic serological observation into a clearly defined, genetically understood blood group system.
About the Author
